These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 17537997)

  • 1. Hepatotoxicity during nevirapine-based fixed-dose combination antiretroviral therapy in kampala, Uganda.
    Hahn JA; Maier M; Byakika-Tusiime J; Oyugi JH; Bangsberg DR
    J Int Assoc Physicians AIDS Care (Chic); 2007 Jun; 6(2):83-6. PubMed ID: 17537997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda.
    Oyugi JH; Byakika-Tusiime J; Ragland K; Laeyendecker O; Mugerwa R; Kityo C; Mugyenyi P; Quinn TC; Bangsberg DR
    AIDS; 2007 May; 21(8):965-71. PubMed ID: 17457090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of nevirapine in HIV-infected pregnant women initiating antiretroviral therapy at higher CD4 counts: a systematic review and meta-analysis.
    Bera E; Mia R
    S Afr Med J; 2012 Oct; 102(11 Pt 1):855-9. PubMed ID: 23116743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya.
    Peters PJ; Stringer J; McConnell MS; Kiarie J; Ratanasuwan W; Intalapaporn P; Potter D; Mutsotso W; Zulu I; Borkowf CB; Bolu O; Brooks JT; Weidle PJ
    HIV Med; 2010 Nov; 11(10):650-60. PubMed ID: 20659176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting.
    Kalyesubula R; Kagimu M; Opio KC; Kiguba R; Semitala CF; Schlech WF; Katabira ET
    Afr Health Sci; 2011 Mar; 11(1):16-23. PubMed ID: 21572852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nevirapine-associated hepatotoxicity and rash among HIV-infected pregnant women in Kenya.
    Peters PJ; Polle N; Zeh C; Masaba R; Borkowf CB; Oyaro B; Omolo P; Ogindo P; Ndivo R; Angira F; Lando R; Fowler MG; Weidle PJ; Thomas TK
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(2):142-9. PubMed ID: 22020069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting.
    Hermans SM; Manabe YC; Kiragga AN; Hoepelman AI; Lange JM; van Leth F
    Antivir Ther; 2013; 18(4):615-22. PubMed ID: 23423604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
    Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
    Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda.
    Spacek LA; Shihab HM; Kamya MR; Mwesigire D; Ronald A; Mayanja H; Moore RD; Bates M; Quinn TC
    Clin Infect Dis; 2006 Jan; 42(2):252-9. PubMed ID: 16355337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine.
    Manfredi R; Calza L; Chiodo F
    HIV Clin Trials; 2005; 6(6):302-11. PubMed ID: 16452064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon.
    Bourgeois A; Laurent C; Mougnutou R; Nkoué N; Lactuock B; Ciaffi L; Liégeois F; Andrieux-Meyer I; Zekeng L; Calmy A; Mpoudi-Ngolé E; Delaporte E
    Antivir Ther; 2005; 10(2):335-41. PubMed ID: 15865228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.
    Wit FW; Kesselring AM; Gras L; Richter C; van der Ende ME; Brinkman K; Lange JM; de Wolf F; Reiss P
    Clin Infect Dis; 2008 Mar; 46(6):933-40. PubMed ID: 18271750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort.
    Calmy A; Pinoges L; Szumilin E; Zachariah R; Ford N; Ferradini L;
    AIDS; 2006 May; 20(8):1163-9. PubMed ID: 16691068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical safety of a generic fixed-dose combination of stavudine/lamivudine/névirapine (Triomune). Study of 297 cases in Togo].
    Mouhari-Touré A; Saka B; Kombat K; Tchangaï-Walla K; Pitche P
    Bull Soc Pathol Exot; 2008 Dec; 101(5):404-6. PubMed ID: 19192611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low frequency of liver enzyme elevation in HIV-infected patients attending a large urban treatment centre in Uganda.
    Ocama P; Castelnuovo B; Kamya MR; Kirk GD; Reynolds SJ; Kiragga A; Colebunders R; Thomas DL
    Int J STD AIDS; 2010 Aug; 21(8):553-7. PubMed ID: 20975087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole.
    Manosuthi W; Athichathanabadi C; Uttayamakul S; Phoorisri T; Sungkanuparph S
    BMC Infect Dis; 2007 Mar; 7():14. PubMed ID: 17352798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study.
    Reliquet V; Allavena C; François-Brunet C; Perré P; Bellein V; Garré M; May T; Souala F; Besnier JM; Raffi F
    HIV Med; 2006 Oct; 7(7):431-6. PubMed ID: 16925728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
    Manosuthi W; Mankatitham W; Lueangniyomkul A; Chimsuntorn S; Sungkanuparph S
    HIV Med; 2008 May; 9(5):294-9. PubMed ID: 18400076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study.
    Keiser P; Nassar N; White C; Koen G; Moreno S
    HIV Clin Trials; 2002; 3(4):296-303. PubMed ID: 12187503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.